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The receptor protein tyrosine phosphatase PTPRB negatively
regulates FGF2-dependent branching morphogenesis
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ABSTRACT
PTPRB is a transmembrane protein tyrosine phosphatase known
to regulate blood vessel remodelling and angiogenesis. Here, we
demonstrate that PTPRB negatively regulates branching
morphogenesis in the mouse mammary epithelium. We show that
Ptprb is highly expressed in adult mammary stem cells and also,
although at lower levels, in oestrogen receptor-positive luminal cells.
During mammary development, Ptprb expression is downregulated
during puberty, a period of extensive of ductal outgrowth and
branching. In vivo shRNA knockdown of Ptprb in the cleared
mammary fat pad transplant assay resulted in smaller epithelial
outgrowths with an increased branching density and also increased
branching in an in vitro organoid assay. Organoid branching was
dependent on stimulation by FGF2, and Ptprb knockdown in
mammary epithelial cells resulted in a higher level of fibroblast
growth factor receptor (FGFR) activation and ERK1/2
phosphorylation, both at baseline and following FGF2 stimulation.
Therefore, PTPRB regulates branching morphogenesis in the
mammary epithelium by modulating the response of the FGFR
signalling pathway to FGF stimulation. Considering the importance of
branching morphogenesis in multiple taxa, our findings have general
importance outside mammary developmental biology.
KEY WORDS: Mammary stem cells, Branching morphogenesis,
PTPRB, FGFR2, Terminal end bud gene expression, Mouse
INTRODUCTION
The mammary gland is a highly dynamic organ; limited embryonic
development is followed by extensive postnatal pubertal
development with further differentiation and tissue remodelling
occurring during pregnancy and lactation (Macias and Hinck,
2012). A key aspect of mammary epithelial structure formation is
branching morphogenesis, a patterning event driven by systemic
and local cues (Sternlicht, 2006). During pubertal development,
branching morphogenesis is dependent on the balance between the
rate of ductal extension driven by terminal end buds (TEBs;
specialised growth structures at the tips of the developing ducts), the
rate of TEB bifurcation and, in the later stages of development, the
formation of lateral branches from established ducts. As branching
morphogenesis is a common developmental process in many tissues
in many taxa, understanding its regulation in the mammary gland
could have implications beyond a single system and be applicable to
similar aspects of development across the animal kingdom.
The growth of TEBs, and thus of the subtending ducts, is driven
by one or more stem cell population(s) which generate the two main
mammary epithelial lineages (‘basal’ and ‘luminal’) during puberty
(Ball, 1998; Srinivasan et al., 2003; Williams and Daniel, 1983).
Stem cells dispersed throughout the mature mammary epithelium
are also thought to be important for maintenance of the adult non-
pregnant gland, although the nature of these remains controversial
(Rios et al., 2014; Van Keymeulen et al., 2011;Wang et al., 2015). It
is clear, however, that the basal layer contains a small population of
cells with potent outgrowth potential in mammary fat pad transplant
experiments and which upon transplantation regenerate complete
basal and luminal layers, consistent with a stem cell identity
(Shackleton et al., 2006; Sleeman et al., 2006; Stingl et al., 2006). In
addition to this transplantable stem cell population, the basal layer
consists mainly of contractile myoepithelial cells. The luminal layer
consists of populations of progenitors (Regan et al., 2012) as well as
functionally differentiated cells, including hormone-sensing
oestrogen receptor (ER)-positive (ER+) cells and the secretory
ER negative (ER–) cells found in the alveoli during lactation.
The luminal progenitors are mainly ER– (Regan et al., 2012). The
molecular regulation of epithelial homeostasis in these stem-
progenitor-differentiated populations, and how this homeostasis
contributes to tissue morphogenesis, remains an area of intense
interest.
PTPRB, also known as RPTPβ and VE-PTP, is a highly
promiscuous R3 type receptor protein tyrosine phosphatase that
can dephosphorylate multiple receptor tyrosine kinases (Barr et al.,
2009). It consists of a single intracellular catalytic domain with C-
terminal phosphorylation sites, a transmembrane domain and an
extracellular domain with multiple fibronection type III-like
domains (Matozaki et al., 2010). Binding by heparin binding
domain-containing growth factors, such as pleiotropin, causes
dimerisation and inactivation (Maeda and Noda, 1998). The role
and functions of PTPRB have been most fully described in the
development of the embryonic vasculature (Baumer et al., 2006;
Dominguez et al., 2007) and in arterial endothelial cells, in which
the two main targets of PTPRB have been identified as the receptor
tyrosine phosphatase TEK and vascular endothelial cadherin
(VE-cadherin; also known as cadherin 5 or CDH5). PTPRB
activity enhances VE-cadherin-mediated adhesion (Nawroth et al.,Received 16 January 2017; Accepted 25 August 2017
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2002) but is a negative regulator of TEK (Baumer et al., 2006;
Dominguez et al., 2007).
We recently identified a set of 323 genes, including Ptprb,
expression of which was specifically associated with the
transplantable basal mammary stem cell (MaSC) population in the
adult mouse mammary epithelium (Soady et al., 2015). As a
regulator of morphogenesis in other systems, we hypothesised that
PTPRB might also be a regulator of mammary development.
However, owing to the embryonic lethality of Ptprb gene ablation
and the lack of a conditional knockout model, the functional role of
PTPRB in postnatal mammary gland development has not
previously been studied. We have therefore exploited the potential
of cleared fat pad transplantation in an in vivo functional genomics
approach as well as in vitro mechanistic studies to determine
whether PTPRB is required for normal mammary morphogenesis.
We find that PTPRB is a negative regulator of branching
morphogenesis, acting by modulating signalling downstream of
FGFR. These results have general importance for understanding the
regulation of epithelial branching morphogenesis.
RESULTS
Expression patterns of Ptprb in the mammary epithelium
alter during postnatal mammary development
In an Affymetrix microarray-based analysis of gene expression in
the adult (10- to 12-week-old) mammary epithelium comparing
highly purified MaSCs with the other major epithelial
subpopulations (myoepithelial cells, luminal ER– progenitors and
luminal ER+ differentiated cells), we identified a 323 MaSC gene
signature that included Ptprb (Soady et al., 2015). We hypothesised
that PTPRB might be a regulator of mammary morphogenesis.
To test this hypothesis, we evaluated Ptprb expression by
quantitative real-time reverse transcriptase PCR (qPCR) during
postnatal mammary gland development in highly purified primary
mammary epithelium subpopulations isolated by flow cytometry at
three developmental time points. MaSC, myoepithelial (MYO),
luminal ER– progenitor (LumER−) and luminal ER+ differentiated
(LumER+) cells were isolated from female FVBnAQ2
¶
mice as previously
described (Regan et al., 2012; Soady et al., 2015) (Fig. S1). The
developmental stages assessed covered pubertal mammary gland
morphogenesis with three time points representing the onset/early
stages of pubertal development (3-4 weeks), mid-puberty
(5-6 weeks) and late puberty/young adulthood (8-10 weeks) (Fig. 1A).
Comparison of expression levels between the cell populations at
each time point (Fig. 1B) demonstrated that at onset of puberty Ptprb
was more highly expressed in LumER+ cells than in MaSCs
(P≤0.01). At mid-puberty, when the majority of ductal outgrowth
occurs, Ptprb expression was not significantly different between the
MaSCs and LumER+ populations. Confirming our previous findings
from the adult gland (Soady et al., 2015), at 8-10 weeks Ptprb was
most highly expressed (P≤0.01) in MaSCs. However, at all time
points, bothMaSCs and LumER+ cells had significantly higher levels
of Ptprb expression than the LumER− and MYO populations.
Comparing expression levels between the time points within each
cell subpopulation (Fig. 1C) showed that for each population Ptprb
expression was reduced at 5-6 weeks (the period of most extensive
epithelial expansion and morphogenesis) compared with expression
levels at 3-4 weeks (P≤0.05 for LumER− cells, P≤0.01 for MYOs,
MaSCs and LumER+ cells). By 8-10 weeks, Ptprb expression in
MaSCs had returned to 3-4 week levels; however, for the LumER+
and MYOs, although Ptprb expression levels were increased
compared with 5-6 week levels, they remained significantly lower
than at 3-4 weeks old (P≤0.01 for both populations).
Consistent with the qPCR expression analysis, and the known
role of PTPRB in endothelial cells, RNAScope in situ hybridisation
localised Ptprb to the endothelial cells of blood vessels in the 3-
week-old mammary gland and to a subset of luminal epithelial cells
in mammary ducts (Fig. S2). In the 6-week-old gland, Ptprb
expression could not be detected in the mammary epithelium, either
because the numbers of cells expressing Ptprb was very low, or, the
expression level per cell had fallen below the threshold for detection
by the technique. However, at this time Ptprb was expressed in a
group of stromal cells surrounding the ducts. Finally, at 12 weeks
Ptprb was again detected in a subset of luminal cells although at
much weaker levels (Fig. S2), consistent with the qPCR. We did not
observe basal cells with a Ptprb signal at any age; however, basal
mammary stem cells are very rare and indeed have never been
definitively identified in histological sections, so this is not
surprising.
As Ptprb expression was below the limits of detection by in situ
hybridisation at 6 weeks, to determine whether Ptprb was
differentially expressed in the two main morphological structures
of the developing gland, the TEBs and their subtending ducts, a
gene expression profile data set of microdissected TEBs compared
with ducts collected at 6-7 weeks was mined for Ptprb expression
(Table S1). This analysis demonstrated that Prprb is expressed at
significantly lower levels in the TEBs compared with the ducts (1.5-
fold lower; P<0.05).
In summary, Ptprb is most highly expressed in MaSCs and
LumER+ cells in the adult mammary epithelium, but its expression
pattern is dynamically regulated during pubertal development.
LumER+ cells have a decrease in Ptprb expression at mid-puberty
followed by a partial recovery; MaSCs also have a decrease in mid-
puberty but a strong recovery in the adult tissue back to levels seen at
pubertal onset. During puberty, Ptprb is expressed at lower levels in
TEBs than in ducts. The strong recovery of expression in MaSCs
compared with the partial recovery in LumER+ cells results in the
MaSCs becoming the highest expressers of Ptprb in the adult gland.
Ptprb knockdown promotes branching morphogenesis
in vivo
The correlation between lower levels of Ptprb expression and the
period of most intense morphogenetic activity in the mammary
gland, suggested that PTPRB may be a negative regulator of
mammary morphogenesis. We tested this in in vivo functional
assays. In the first series of experiments, primary mouse mammary
epithelial cells were transduced in short-term culture (48 h) with
either a pooled lentiviral supernatant containing two shRNA
sequences against Ptprb (shPtprb pool consisting of shPtprb 0145
plus shPtprb 3820) or a control shRNA designed to target luciferase
(shLuc). In a second series of three independent experiments,
primary cells were transduced in short-term culture with one of two
different lentiviral constructs carrying shRNA sequences targeting
Ptprb (shPtprb 0145 or shPtprb 3820) or with a lentvirus carrying a
scrambled sequence (shScr). In both sets of experiments the viral
vectors also contained GFP to mark transduced cells and
supernatants were diluted to ensure both control and shPtprb
supernatants contained equal viral titres. The efficacy of the shPtprb
pool and the individual lentiviruses in suppressing Ptprb expression
was confirmed by qPCR (Fig. 2A,B). Transduced cells were
transplanted into cleared mammary fat pads at 50,000 cells per fat
pad. At 8 weeks, fat pads were harvested and examined under
epifluorescent illumination, after which they were processed for
flow cytometric analysis to assess the relative proportions of the
epithelial cell populations.
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Therewere no differences in the number of successful outgrowths
between the shLuc (8 outgrowths from 11 transplanted fat pads;
n=2 independent experiments) and the shPtprb pool (11/11;
n=2 independent experiments) transplants or between the shScr
(23/24; n=3 independent experiments), the shPtprb 0145 (13/13;
n=3 independent experiments) and the shPtprb 3820 (11/13; n=3
independent experiments) transplants. However, Ptprb-knockdown
transplants appeared to be more densely branched but filled less of
the total area of the fat pad than the control outgrowths (Fig. 2C).
Quantification of the area of the outgrowths and of the number of
branch points per mm2 confirmed that knockdown outgrowths were
significantly smaller than control outgrowths but more densely
branched (Fig. 2D,E).
Both control and Ptprb-knockdown outgrowths had distinct
luminal [keratin 18 (K18; KRT18AQ3
¶
) positive] and basal/
myoepithelial [smooth muscle actin (SMA; ACTA2) positive]
layers (Fig. 3A). Flow cytometric analysis of the outgrowths
confirmed that there were no differences in the proportions of the
major epithelial populations (Fig. S3). Ki67 (Mki67) staining of
control and Ptprb-knockdown transplants demonstrated that, at the
time point at which the transplants were harvested, there was little or
no proliferation in control tissue but Ptprb-knockdown tissue was
highly proliferative (Fig. 3B). However, the smaller size and denser
branching of the knockdown tissue (meaning that sections were more
likely to be enriched for the TEBs) is an important caveat in this
analysis. In the proliferating Ptprb-knockdown tissue, equivalent
numbers of Ki67-positive cells were observed in SMA-positive basal
and SMA-negative luminal layers (Fig. 3B,C). Little or no cleaved
caspase-3, a marker of apoptosis, could be detected in either control
or Ptprb-knockdown outgrowths (Fig. S4B).
To determine whether Ptprb knockdown perturbed stem cell
function as assessed by engraftment potential, GFP-positive regions
from a series of successful shScr and shPtprb 0145 primary
transplants were dissected out, digested to single cells and then
re-transplanted. Take rates for secondary transplantation into
contralateral fat pads of shScr- and shPtprb 0145-transduced cells
were 8/9 for both the control and knockdown cells. Consistent with
the primary transplants, shPtprb 0145-transduced outgrowths had
a significantly smaller area than control outgrowths (Fig. 3D,
Fig. S4C). Overall, these findings show PTPRB does not affect stem
cell engraftment potential or lineage determination, but does
regulate mammary branching morphogenesis.
Fig. 1. Ptprb expression is repressed in mid-pubertal
mammary epithelial cells. (A) Whole-mount fourth
mammary fat pads from FVB mice at 3-4, 5-6 and 8-
10 weeks of age illustrating the extent of ductal development.
Scale bars: 3 mm. Inset shows enlargement (5×) of the
boxed area of the 3-4 week fat pad to show terminal end
buds. (B) Relative Ptprb expression between MaSC and
MYO, MaSC and LumER−, and MaSC and LumER+
populations determined by qPCR at three time points. The
comparator sample is the LumER− population at each age
group. (C) Relative Ptprb expression within each population
across the three time points. Comparator was the 4-week-old
sample for each population. Significance comparisons
between 3-4 week and 5-6 week, between 3-4 week and
8-10 week and between 5-6 week and 8-10 week
populations are indicated. **P<0.01, *P<0.05, N.S., not
significant. Data in B and C were from three independent
isolates of each cell population at each age. Data were
normalised to β-actin (Actb) and expressed as mean log10
relative fold expression (±95% confidence intervals) over the
comparator.
3
RESEARCH ARTICLE Development (2017) 0, 1-12 doi:10.1242/dev.149120
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
Ptprb knockdown promotes branching morphogenesis in an
in vitromodel system in an FGF-dependent manner
To provide further support for a role for PTPRB in regulating
branching morphogenesis and to establish a model in which the
mechanism of action of PTPRB could be addressed, we utilised an
in vitro branching morphogenesis assay (Ewald et al., 2008). Small
fragments of mammary epithelial ducts, which retain the basal-
luminal bilayered architecture (‘organoids’), were either left
untransduced or transduced with shScr, shPtprb 0145 or shPtprb
3820 lentiviruses, embedded in Matrigel and treated for 5 days with
medium containing FGF2, which stimulates branching in this
system (Ewald et al., 2008). The total number of organoids and
number of branched organoids were counted; branched organoids
were defined as an organoid with at least one branch protruding
from the main spherical body.
Organoid cultures branched only in the presence of FGF2; in the
absence of FGF2, Ptprb knockdown alone was not sufficient to
stimulate branching (Fig. S5A). However, knockdown of Ptprb in
FGF2-stimulated cultures significantly increased (P≤0.05) the
number of branched organoids, with 40% of organoids branching
in non-infected and Scr controls to >60% in shPtprb1 0145 and
shPtprb2 3820 cultures (Fig. 4A). The amount of branching in non-
infected and Scr controls was consistent with previous reports on
branching in unmanipulated primary mammary epithelial organoids
(Macias et al., 2011). Therefore, Ptprb knockdown in vitro
increased the number of organoids competent to branch under
FGF2 stimulation.
To assess whether Ptprb knockdown also affected the extent of
branching, the degree of branching in all branched organoids was
ascertained. Branched organoids were categorised into low (1-5
branches), intermediate (6-15 branches) or highly branched (>15
branches) organoids (Fig. 4B,C). Compared with control cultures,
shPtprb 0145- and shPtprb 3820-transduced organoids had an
increase in the proportion of highly branched organoids and a
reduction in numbers of organoids with low branching levels
(Fig. 4C). Therefore, in vitro knockdown of Ptprb increased both
the percentage of branched mammary epithelial organoids and the
number of branches on each branched organoid, but only under
conditions of growth factor stimulation.
Endogenous Ptprb expression is downregulated during
in vitro branching morphogenesis
In vivo, levels of endogenous Ptprb expression are suppressed
during the period of postnatal mammary development. To
determine if similar changes in Ptprb expression occur during
organoid branching in vitro, and to characterise in more detail the
relationship between the kinetics of endogenous Ptprb expression
Fig. 2. Ptprb knockdown promotes branching morphogenesis
in vivo. (A) qPCR analysis of Ptprb gene expression in non-
transduced primary mouse mammary epithelial cells and in cells
transduced with either an empty virus, a control virus carrying a
scrambled oligonucleotide sequence (shScr), a sequence targeting
luciferase (shLuc), or a virus pool consisting of two viruses (shPtprb
0145 and 3820) targeting Ptprb. (B) qPCR analysis of Ptprb gene
expression in non-transduced cells and cells transduced with shScr
virus or the individual shPtprb 0145 and shPtprb 3820 viruses. Data
in A,B are presented as mean fold Ptprb expression (±95%
confidence intervals; n=3 independent experiments) over
comparator (non-transduced cells). *P<0.05 compared with non-
transduced cells; **P<0.01 compared with non-transduced cells;
##P<0.01 compared with shLuc or shScr-transduced cells.
(C) Representative images of GFP+ outgrowths in whole-mount fat
pads 8 weeks after transplant of control- or shPtprb-transduced
cells. Scale bars: 5 mm. Insets showenlargements (×3) of the boxed
areas. Branch points in insets are indicated by arrowheads. For each
shPtprb fat pad, the control shown next to it is a transplanted
contralateral gland from the same animal. (D,E) Analysis of size
(D) and branching (E) of control and shPtprb knockdown outgrowths
(mean±s.e.m.). *P<0.05, **P<0.01, ***P<0.001. shLuc and shPtprb
data from two independent transplant experiments; shScr, shPtprb
0145 and shPtprb 3820 data from three independent experiments.
Numbers of fat pads analysed are provided in Fig. S4A.
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and branching, unmanipulated non-infected organoids were
embedded in Matrigel and stimulated with or cultured without
FGF2 for 6 days. Non-stimulated organoids did not grow or branch
over the experimental time course whereas stimulated organoids
expanded in size and produced branches, with the first obvious
branching apparent by day 4 (Fig. 5A). qPCR analysis of Ptprb
expression in FGF2-stimulated branching organoids showed that
Ptprb expression was reduced over time in stimulated organoids
relative to day 0. The reduction in Ptprb expression was significant
from day 1, decreased further at day 3 and remained low until the
end of the time course (Fig. 5B).
To control for the possibility that the decrease in Ptprb expression
was related to the time in culture rather than correlated with FGF2
stimulation and concomitant branching, levels of Ptprb expression
in stimulated organoids were compared with non-stimulated
organoids at each time point (Fig. 5C). This demonstrated that
Ptprb expression in stimulated organoids was significantly lower
than in non-stimulated organoids by day 3 and continued to drop at
days 4 and 5. Importantly, these findings showed that the first
significant difference between Ptprb levels in non-stimulated and
stimulated organoids was seen just before (day 3) the stimulated
organoids initiated branching (day 4). This suggests a temporal
correlation between FGF2 stimulation, Ptprb expression and
branching.
PTPRB acts on FGFR-ERK1/2 signalling to inhibit mammary
branching morphogenesis
The in vivo and in vitro findings, taken together, suggested that
although PTPRB does not directly inhibit mammary
morphogenesis, it acts as a negative regulator of signalling
pathways that promote branching morphogenesis. In this model,
suppression of Ptprb expression would result in either a higher or
more sustained level of signalling by pro-branching pathways. We
already demonstrated using an organoid culture system that PTPRB
expression interacted with FGF signalling in vitro. To determine
whether there was evidence for an interaction between PTPRB and
FGF signalling in vivo, and to assess the possibility that PTPRB
regulates other signalling pathways associated with mammary
branching morphogenesis, we used qPCR to examine the
expression of three receptor tyrosine kinases (Erbb2, Egfr and
Tek) previously suggested to interact with PTPRB and with
potential roles in mammary branching morphogenesis (Andrechek
et al., 2005; Chodosh et al., 2000; Wiesen et al., 1999). We also
examined expression of three receptor kinases, including two
members of the FGF receptor family (Fgfr1, Fgfr2 and Igfr1 AQ4
¶
), not
previously described as interacting with PTPRB but known to play
an important role in mammary development (Lu et al., 2008; Pond
et al., 2013; Sternlicht et al., 2006). Patterns of expression in the
different mammary epithelial subpopulations at the 5-6 week
Fig. 3. Ptprb knockdown increases mammary epithelial cell
proliferation. (A,B) Staining of sections of shLuc (top rows) and
shPtprb (bottom rows) outgrowths with anti-SMA and DAPI and
either anti-K18 (A) or anti-Ki67 (B) antibodies. Arrowheads indicate
xxxxxxxxxxxxxx. Scale bars: 100 μm. (C) Quantification of Ki67
staining in luminal (SMA−) and basal (SMA+) layers of shPtprb
outgrowths. Data are shown as mean±s.e.m. (n=8 regions from
three independent control outgrowths and 11 regions from three
independent Ptprb-knockdown outgrowths). (D) Analysis of areas
(mm2) of outgrowths of shScr (n=8) and shPtprb 0145 (n=8)
secondary transplants (mean±s.e.m.). *P<0.05; N.S., not
significant.
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developmental time point (when branching morphogenesis in the
mammary epithelium is maximal) were determined and compared
with the previously established pattern of Ptprb expression
(Fig. 6A). This analysis showed a strong correlation between
Ptprb expression and the patterns of Fgfr2 and Tek expression
across the subpopulations, but no correlation with Egfr, Fgfr1 or
Igfr1 expression.
Next, expression of Fgfr2 and Tek across the 3-4 week, 5-6 week
and 8-10 week time course was examined and compared with Ptprb
(Fig. 6B,C). We concentrated on expression patterns in the MaSCs
and LumER+ cells, as these two populations showed the highest
levels of Ptprb, Fgfr2 and Tek at 5-6 weeks. Expression of Tek in
LumER+ cells was significantly lowered in 5-6 week animals
relative to 3-4 weeks. However, by 8-10 weeks it was back to
3-4 week levels (Fig. 6B). By contrast, Tek levels in MaSCs were
not significantly different between 3-4 weeks and 5-6 weeks and
then fell significantly at 8-10 weeks. Thus, there were similarities
between Tek and Ptprb expression patterns in LumER+ cells,
although these were not exact. However, there were no obvious
correlations between Tek and Ptprb expression in MaSCs (Fig. 6C).
Fgfr2 expression levels were not significantly different in the
LumER+ cells between 3-4 weeks and 5-6 weeks but were
significantly increased at 8-10 weeks. However, in MaSCs, there
was a significant increase in Fgfr2 expression at 5-6 weeks
compared with 3-4 weeks, and then a decrease AQ5
¶
in expression.
Therefore, there was no obvious correlation between Ptprb and
Fgfr2 expression in LumER+ cells but there was an inverse
correlation between the Ptprb and Fgfr2 expression patterns in the
MaSCs (Fig. 6B,C).
Fig. 4. Ptprb knockdown promotes branching morphogenesis in an
in vitromodel system. Non-infected (NI), shScr-, shPtprb 0145- and shPtprb
3820-transduced organoids were embedded in Matrigel and stimulated to
branch with FGF2 for 5 days in culture. Data from three independent
experiments (duplicate wells for each treatment per experiment). GFP
expression was used as a marker of lentivirus infection. (A) Number of
branched organoids as a percentage of the total number of organoids (mean±
s.d.). *P<0.05 (t-test). (B) Representative images (merged GFP fluorescence
and phase contrast) of organoids with no branching (0 branches), low-level
branching (1-5 branches), intermediate-level branching (6-15) and high-level
branching (>15) Scale bars: 30 μm. (C) Extent of branching in non-infected
(NI), shScr and Ptprb knockdown organoids. The proportion of organoids with
low-, intermediate- or high-level branching is shown as a percentage of the total
number of branched organoids per treatment. *P<0.05; **P<0.01 (χ2 test of
distribution of categorical variables).
Fig. 5. FGF2 suppresses Ptprb expression in vitro. (A) Representative
images of unmanipulated organoids in 3D culture either ‘non-stimulated’
(without growth factor; top panel) or ‘stimulated’ (with FGF2; bottom panel).
Scale bars: 100 µm. Arrowheads indicate branches emerging at day 4. Insets
show enlarged (2.5×) images of the organoids marked by asterisks. (B,C)
Ptprb expression in non-stimulated and stimulated organoids, taken at 24 h
time points for 6 days, determined by qPCR. Data normalised to β-actin (Actb)
and expressed as mean log10 relative fold expression (±95% confidence
intervals) over comparator population. Data were collected from three
independent organoid preparations. (B) Ptprb expression in stimulated
organoids using the day 0 time point as the comparator sample. **P<0.01
compared with day 0; #P<0.01 compared with day 2 (t-tests). (C) Ptprb
expression in non-stimulated and stimulated organoids with expression levels
in stimulated organoids compared with non-stimulated organoids at the same
time point. **P<0.01 relative to comparator.
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The in vitro organoid assay had already demonstrated that
treatment with the FGFR ligand FGF2 promotes branching
morphogenesis whilst suppressing Ptprb expression, supporting
the inverse correlative relationship between Fgfr2 and Ptprb
expression in vivo. We now tested whether two ligands for TEK,
angiopoietin 1 and 2 (ANG1 and 2; also known as ANGPT1 and 2),
could substitute for FGF2 in this assay. However, neither was able to
stimulate branching (Fig. S5B), suggesting that the ANG-TEK axis
is not involved in mammary branching morphogenesis. We
therefore focussed on FGFR signalling and addressed whether
PTPRB is a negative regulator of this pathway.
As PTPRB is a cell surface receptor phosphatase, we
hypothesised that it might be regulating phosphorylation of FGF
receptors. We therefore tested in three independent experiments
whether Ptprb knockdown altered baseline levels of FGFR
phosphorylation as well as the response to FGF2. Indeed,
transduction with the shPtprb 3820 virus significantly increased
FGFR phosphorylation over shLuc control, both baseline levels and
in response to FGF2. The effects of shPtprb 0145 were more
modest, with a significant difference only seen after five minutes of
FGF2 treatment (Fig. 7A, Fig. S6). Note that pFGFR antibodies
cannot distinguish between the FGFR receptor isoforms, so it is not
possible to determine which (or indeed if more than one) of the
family shows increased phosphorylation in response to Ptprb
knockdown. However, by using non-phospho-specific antibodies
which do distinguish between the isoforms, we were able to
demonstrate that total levels of FGFR1, 2, 3 and 4 were not changed
when Ptprb was knocked down (Figs S7 and S8), confirming that
the increase in pFGFR levels was indeed due to increased receptor
phosphorylation rather than to increased receptor expression.
We next tested whether Ptprb knockdown altered the response of
a downstream effector of FGF signalling, ERK1/2 (also known as
MAPK3/1), to FGF2. First, we confirmed that branching in the
organoid culture system in response to FGF2 was dependent on
ERK1/2 activity, using a small molecule inhibitor of ERK
(SCH772984; Figs S9 and S10). Next, organoids cultured in the
in vitro branching assay system were transduced with either shLuc,
shPtprb 0145 or shPtprb 3820 knockdown virus and protein lysates
collected either from unstimulated cultures or from cultures after 5,
15 and 60 min of FGF2 stimulation. In three independent
experiments, Ptprb knockdown by both shPtprb 0145 and
shPtprb 3820 resulted in a statistically significant increase in
unstimulated baseline ERK1/2 phosphorylation compared with
shLuc controls. In response to FGF2 stimulation, shPtprb 3820
cultures continued to show statistically significantly higher levels of
phosphorylation at all time points, over and above the increased
phosphorylation resulting from activation of the pathway. shPtprb
0145 cultures also showed higher mean phosphorylation but the
differences in stimulated cultures were not statistically significant
(Fig. 7B, Fig. S11).
Finally, FGF-stimulated organoids in which Ptprb had been
knocked down by either shPtprb 0145 or shPtprb 3820, were treated
with SCH772984. In control cultures, knockdown organoids
showed increased branching in response to FGF, as previously.
However, treatment with the inhibitor partially restored branching
back to control levels in shPtprb 0145-transduced cultures and fully
restored control branching levels in shPtprb 3820 cultures (Fig. 7C).
Taken together, these findings support the model that PTPRB
suppresses branching morphogenesis via inhibition of the FGFR2-
ERK1/2 signalling axis.
Fig. 6. Analysis of expression of candidate PTPRB-
interacting receptor tyrosine kinases in mammary
epithelial subpopulations. (A) Relative Ptprb, Fgfr2, Tek,
Egfr, Fgfr1 and Igfr1 expression in MaSCs, MYOs, LumER−
and LumER+ populations determined by qPCR at mid-
puberty (5-6 week samples). The comparator sample is the
LumER− population in all cases. Ptprb data reproduced
from Fig. 1 for reference. **P<0.01 versus LumER−,
*P<0.05 versus LumER− ; ##P<0.01 versus MYO AQ11
¶
,
^^P<0.01 versus LumER+, ^P<0.05 versus LumER+. For
simplicity, significance is only shown compared with lower
expressing samples. (B,C) Relative Ptprb, Fgfr2 and Tek
expression in LumER+ cells (B) and MaSCs (C) at 3-4, 5-6
and 8-10 weeks of age. The comparator was the 4-week-old
sample for each population. Datawere normalised to β-actin
(Actb) and expressed as mean log10 relative fold
expression (±95% confidence intervals) over the
comparator. Data from three independent isolates of each
cell population at each age. Ptprb data reproduced from
Fig. 1 for reference. **P<0.01 versus 3-4 week samples AQ12
¶
.
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DISCUSSION
Mammary epithelial development is a highly regulated process
dependent on the interplay between systemically acting hormones
and locally produced growth factors. During puberty rising levels of
the ovarian steroid hormones oestrogen and progesterone, growth
hormone secreted from the pituitary gland and locally produced
growth factors cause a significant increase in ductal growth
(Hennighausen and Robinson, 2001; Macias and Hinck, 2012).
This growth is driven by bulbous TEBs, which form at the tips of
elongating primary ducts and regularly bifurcate to form the primary
branches of the ductal epithelium. As the mammary tree matures,
secondary side branches sprout laterally at regular intervals, from
which will form the tertiary lateral branches that occur at each
dioestrus and during pregnancy. The TEB-tipped ducts grow until
they reach the edge of the fat pad. At this stage, the TEBs regress and
the subtending duct becomes relatively quiescent, leaving the
branched ductal structures of the mature virgin gland (Hens and
Wysolmerski, 2005). The unique ‘open architecture’ of the non-
pregnant gland suggests that branching morphogenesis is a highly
regulated process, involving orchestrated ductal elongation, TEB
bifurcation and lateral branching, which ensures space for additional
proliferation and the formation of alveoli during pregnancy. A
number of positive regulators of this process have been reported,
such as the oestrogen/oestrogen receptor alpha (ER) axis and its
downstream effectors, the growth hormone/growth hormone
receptor/insulin-like growth factor 1 axis, epidermal growth factor
receptor (EGFR) signalling and fibroblast growth factor receptor
(FGFR) signalling. However, few negative regulators have been
identified, transforming growth factor beta 1 (TGFβ1) and sprouty 2
(SPRY2) being notable exceptions (Sternlicht, 2006; Sternlicht
et al., 2006). Here, we have now identified PTPRB as a novel
negative regulator of this process.
In arterial endothelial cells, PTPRB activity enhances VE-
cadherin-mediated adhesion (Nawroth et al., 2002) but is a negative
regulator of TEK. Use of PTPRB-inactivating antibodies in adult
mice triggered activation of TEK, resulting in increased downstream
signalling via ERK1/2, which in turn caused increased endothelial
cell proliferation and enlargement of vascular structures
(Winderlich et al., 2009). Thus, PTPRB is required to balance
TEK activity and endothelial cell proliferation, thereby controlling
blood vessel development and vessel size. This is supported by
work in two independent germline Ptprb mouse knockout models,
Fig. 7. PTPRB suppresses FGFR2 AQ13
¶
signalling by
negatively regulating ERK1/2. (A,B) Western blot analysis
of phospho-FGFR levels (A) and phospho- and total-ERK1/2
levels (B) in shLuc-, shPtprb 0145- and shPtprb 3820-
transduced primary mouse organoid cultures either
unstimulated or stimulated with FGF2 for 5, 15 and 60 min.
Blots are representative of three independent experiments;
quantification of phospho:total ERK1/2 ratios and phospho-
FGFR:tubulin loading control ratios are shown next to the
blots (mean±s.e.m.). *P<0.05 compared with shLuc control at
that time point. The original blots are shown in Figs S6 and
S11. (C) Extent of branching in bFGF-stimulated shScr-
organoids (Scr) and Ptprb knocked-down organoids (0145
and 3820) stimulated with bFGF and treated (or not) with
SCH772984 (2 nM; ERK1/2 i). *P<0.05; ***P<0.01 versus
control FGF-stimulated samples (χ2 test of distribution of
categorical variables); N.S. not significant.
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in which embryonic lethality occurred at around 10 days gestation
owing to severe vascular defects. In both models, vasculogenesis
occurred normally but angiogenesis was severely affected leading to
the deterioration of the intra-embryonic vascular system and
lethality, demonstrating an essential role for PTPRB in
angiogenesis and blood vessel remodelling (Baumer et al., 2006;
Dominguez et al., 2007).
In contrast to angiogenesis, in the mammary epithelium we find
that PTPRB regulates morphogenesis by modulating FGFR
signalling rather than TEK signalling. FGFRs can activate a
number of potential downstream pathways, including PI3K/PIP2/
AKT, PLCγ/IP3/Ca2+/calmodulin and SOS/RAS/RAF/MEK/ERK.
FGFR stimulates the SOS/RAS/RAF/MEK/ERK pathway by
phosphorylation of fibroblast growth factor receptor substrate 2
(FRS2), which in turn recruits GRB2, activating SOS and the
downstream cascade (Katoh, 2009). Notably, SPRY2, another
negative regulator of branching morphogenesis (Sternlicht, 2006;
Sternlicht et al., 2006) is a negative regulator of FGF-induced ERK
pathway activation (Rubin et al., 2005), probably acting
downstream of the GRB2-SOS complex (Gross et al., 2001).
Here, we have demonstrated that knockdown of PTPRB results
in higher baseline levels FGFR phosphorylation, resulting in
higher levels of downstream p-ERK1/2 and a more sustained
response to FGF2 stimulation, leading to a more densely
branched mammary tree.
Evidence is emerging that PTPRB might be a tumour suppressor
gene in a variety of cancers. Recurrent PTPRB loss-of-function
mutations have been identified in angiosarcoma (in 10 of 39
tumours examined) (Behjati et al., 2014), consistent with its normal
role in angiogenesis, but also in metastatic melanoma (9 tumours
with missense, nonsense or splice-site mutations out of a 97 tumour
set) (Ding et al., 2014). Homozygous single nucleotide variations in
PTPRB have also been reported in a rare family with siblings with
glioblastoma multiforme; the parents were heterozygous for the
mutations (Backes et al., 2014). No specific study of PTPRB in
breast cancer has been undertaken, although Ptprb is a component
of the MaSC gene signature we have identified as being prognostic
in breast tumours (Soady et al., 2015). In contrast, a link between
FGFR2 and breast cancer is well-established. FGFR2 gene
amplification and FGFR2 protein overexpression (especially of C-
terminally truncated products) occurs in primary ER+ breast cancer
(Adnane et al., 1991; Katoh, 2003). The C-terminally truncated
product can activate signalling cascades in a ligand-independent
manner (Moffa and Ethier, 2007). Missense point mutations also
occur in primary breast cancer (Stephens et al., 2005) and single
nucleotide polymorphisms in intron 2 of FGFR2 are associated with
an increased risk of ER+ breast cancer (Easton et al., 2007). Our
findings suggest FGFR2 and PTPRB should be considered as part
of an integrated signalling pathway when assessing the activity of
receptor tyrosine kinase signalling cascades in breast cancer.
Our study does have limitations, including potential off-target
and non-specific toxic effects of shRNA, as well as potential
variable levels of viral infection and variable tropisms to different
cell types. To offset the issue of infection levels, we chose a
minimum cut-off of 30% GFP-positive cells for analysis of
organoids based on previously published work (Macias et al.,
2011). Furthermore, the pattern of expression of FGF receptors in
organoid cultures is unknown and any period of culture might alter
the behaviour of epithelial cell subtypes compared with the in vivo
situation. Nevertheless, the results of the study as a whole are
consistent in supporting a role for PTPRB in regulating FGF-
dependent branching morphogenesis.
We cannot definitively distinguish between a role for PTPRB in
TEB bifurcation, ductal elongation or lateral branching. However,
the increased density of branching shown in Ptprb transplant
outgrowths must have resulted from either a decrease in the rate of
ductal elongation or an increase in the rate of formation of new
branch points (either by TEB bifurcation or lateral branching). Ptprb
knockdown resulting in a decrease in ductal elongation would not
be consistent with our in vitro findings that Ptprb-knockdown
organoids have more branches in response to FGF treatment.
Furthermore, higher expression of Ptprb in subtending ducts
relative to TEBs is at least correlative evidence that Ptprb could
be suppressing lateral branching during ductal elongation, although
the TEBs versus ducts study was carried out using C57/Bl6 mice,
rather than FvB, and the possibility of strain-specific differences
cannot be definitively excluded. Despite this caveat, when
considered as a whole the data favour a model in which PTPRB is
a negative regulator of FGFR-dependent branching, rather than
ductal elongation.
PTPRB has been typically characterised as a ‘vascular
endothelial-specific’ phosphatase (Behjati et al., 2014). However,
it is becoming clear that it has a wider role in other tissues. Its
function in branching morphogenesis in both the vasculature and, as
we have now shown, the mammary epithelium suggests that PTPRB
is a fundamental regulator of this developmental programme
irrespective of organ system. Furthermore, its emerging role in
cancer and the established importance of the pathway it regulates to
tumour biology, reaffirm the relevance of developmental signalling
programmes to the biology of malignant disease.
MATERIALS AND METHODS
Preparation of mammary epithelial cells for flow cytometry
All animal work was carried out under UK Home Office project and
personal licences following local ethical approval by the Institute of Cancer
Research Animal Ethics Committee and in accordance with local and
national guidelines. Single cells were prepared from fourth mammary fat
pads of virgin female FVB mice as described (Regan et al., 2013) and
stained with anti-CD24-FITC (clone M/69 at 1.0 µg/ml; BD Biosciences,
553261), anti-Sca-1-APC (clone D7 at 1.0 µg/ml; eBioscience, 17-5981),
anti-CD45-PE-Cy7 (clone 30-F11 at 1.0 µg/ml; BD Biosciences, 552848),
anti-CD49f-PE-Cy5 (clone GoH3 at 5.0 µl/ml; BD Biosciences, 551129)
and anti-c-Kit-PE (clone 2B8 at 1.0 µg/ml; BD Biosciences, 553355).
Mammary epithelial cell subpopulations were defined as shown in Fig. S1.
For sorting of GFP+ cells harvested from transplanted fat pads, the
combination of anti-CD24-Pacific Blue (clone M/69 at 1.0 µg/ml; BD
Biosciences, 561079), anti-Sca-1-APC, anti-CD45-PE-Cy7 and DAPI was
used. DAPI-positive dead cells are distinguishable from Pacific Blue-
stained cells by their very bright fluorescence.
Gene expression analysis by quantitative real-time RT-PCR
(qPCR)
Freshly sorted primary cells were lysed in RLT buffer (Qiagen) and stored at
−80°C. Total RNAwas extracted using an RNeasy MinElute Kit (Qiagen),
according to the manufacturer’s instructions. For cultured organoids, RNA
was isolated with Trizol (Invitrogen). qPCR reactions were performed as
previously described using either TaqMan assays or in-house designed
probes (Table S2) (Kendrick et al., 2008). All results were calculated using
the ΔΔCt method compared with an endogenous control gene. Data were
expressed as the mean fold gene expression difference in three
independently isolated cell preparations over a comparator sample with
95% confidence intervals.
RNAScope in situ hybridisation for Ptprb
RNAScope for Ptprb was performed on 5 µm sections using RNAscope 2.5
HD Duplex Reagent Kit using manufacturer’s instructions (Advanced Cell
Diagnostics). RNAscope Control Slides -Mouse 3T3 Cell Pellet were used
9
RESEARCH ARTICLE Development (2017) 0, 1-12 doi:10.1242/dev.149120
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
to test the protocol. Briefly, sections were cut and left to dry overnight at
room temperature. Samples were then baked at 60°C for 1 h, then de-
paraffinisation was performed (2×5 min in fresh xylene), which was
followed by 2×1 min in 100% ethanol. Sections were then left to dry 5 min
at room temperature. Pretreat1 (H202) was then applied and left 10 min at
room temperature followed by two washes in distilled H20. Slides were then
left to boil in Pretreat2 (antigen retrieval) for 15 min and were then washed
twice in distilled water (2×5 min). Preatreat3 (protease) was applied on the
slides for 30 min at 40°C. After two brief washes in distilled water, warmed
probes were applied for 2 h at 40°C: RNAscope 2-plex Negative Control
Probe (320751), Mm-Ptprb Cat No. 481391 in C2 channel (red), RNAscope
2.5 Duplex Positive Control Probe (Mm) PPIB-C1 (Green)/POLR2A-C2
(Red). After two washes in the wash buffer, slides were left at room
temperature overnight in 5×SSC. The next day, slides were incubated with
several rounds of amplification Amp1-10 reagents followingmanufacturer’s
instruction to detect red and green signal. Slides were finally counterstained
5 s in 50% filtered Mayer’s Haemalum (Lamb/170D) and washed briefly in
water then baked for 30 min at 60°C. The slides were mounted using
Vectamount (60 ml) (Vector Laboratories, 321584).
Isolation of TEB and duct fragments
Stromal-free TEBs and ducts were isolated as described previously (Morris
and Stein, 2017;Morris et al., 2006). Briefly, C57BL/6 micewere humanely
killed at 6-7 weeks (16-18 g) and the inguinal mammary glands were
dissected and collected in chilled L15 medium. Twenty glands were pooled
for each preparation, coarsely cut with scalpels and digested with 1 mg/ml
(w/v) collagenase Type II (Sigma) at 37°C for 20-30 min (for TEBs) or 30-
45 min (for ducts) with mild agitation. After incubation, the epithelium was
further freed of the stroma by vigorous shaking by hand. The collagenase
was diluted and blocked with fresh cold L15mediumwith 0.1% fetal bovine
serum (FBS) and the epithelium spun down at 250 g for 5 min. The pellet
was re-suspended in fresh cold L15 medium with 10% FBS, transferred to a
gridded 60 mm dish, and released TEB and ducts were collected under a
stereo dissection microscopewith a 10 μl pipette into 50-100 μl TRI-reagent
(Sigma) before snap-freezing.
RNA isolation and microarray hybridisation from isolated
epithelium
For RNA isolation, frozen samples were thawed and RNA isolated
according to manufacturer’s protocol before re-suspension in RNase-free
water. The RNA was quantified with a Nanodrop ND-1000
spectrophotometer, pooled and subjected to on-column DNase I treatment
(Qiagen) and further concentration using a RNeasy-Micro kit (Qiagen).
RNA quality was finally assessed using a 2100 Bioanalyzer and RNA 6000
Nano kit (both Agilent).
For microarray hybridisation, 1.5 μg RNA per sample (from ∼300-400
isolated TEBs or ducts) was used in pooled duplicates and analysed at the
Henry Wellcome Functional Genomics Facility (Glasgow). rRNA was
removed using a RiboMinus Human/MouseTranscriptome Isolation kit and
RiboMinus magnetic beads, labelled according to manufacturer’s protocol
and finally hybridised to mouse whole-genome exon arrays (GeneChip-
Mouse-Exon-1.0-ST-Array, Affymetrix UK) using a GeneChip Fluidics
Station 450/250. The signals were measured using a GeneChip Scanner
3000 7G. CEL-files were analysed and normalised by RMA using the open-
source ‘Altanalyze’ software (Emig et al., 2010). Results of differentially
abundant RNAs in TEBs and ducts were ranked according to raw P-value
[one-way analysis of variance (ANOVA)] (Table S1). Raw data files have
been submitted to Gene Expression Omnibus with the accession number
GSE94371.
Lentivirus production
Oligonucleotide pairs for shPtprb#1 (CACCGCGTCACCCTGTAACTTT-
AGCCGAA GCTAAAGTTACAGGGTGACGC and AAAAGCGTCA-
CCCTGTAACTTTAGCTTCGGC TAAAGTTACAGGGTGACGC) and
shPtprb#2 (CACCGCAAACACCTCCTTGGCTATCC GAAGATAG-
CCAAGGAGGTGTTTGC and AAAAGCAAACACCTCCTTGGCTA-
TCTT CGGATAGCCAAGGAGGTGTTTGC) were ligated into pENTR/U6
Gateway system entry vector (Invitrogen) according to the manufacturer’s
instructions. Hairpin sequences were verified and then transferred, together
with the U6 promoter, into a Gateway-modified pSEW lentiviral vector
backbone (Vafaizadeh et al., 2010 AQ7
¶
) by LR reaction (Invitrogen). Viral
supernatants were generated by Lipofectamine 2000 (Invitrogen, 11668-019)
co-transfection of the packaging and viral DNA sequence plasmids into
HEK293T cells. Cells were re-fed with fresh medium (Dulbecco’s Modified
Eagle’s Medium, DMEM; Invitrogen) plus 10% fetal calf serum (FCS) (PAA
Laboratories, GE Healthcare) after 24 h. Supernatants were harvested 48 and
72 h after transfection and assayed for absence of replication-competent virus.
Supernatants were stored at −80°C until use. For transplantation assays,
primary mammary cells were transduced with lentivirus using the suspension
method as described (Kendrick et al., 2008). Supernatants were adjusted by
dilution where necessary to ensure comparable viral titres prior to transduction.
Mammary epithelial cell transplantation
Transplantation of lentivirus-transduced primary FVB mouse mammary
epithelial cells into cleared fats pads of athymic Ncr Nude mice was carried
out as described (Britt et al., 2009; Sleeman et al., 2007). Fat pads were
harvested 8 weeks after transplantation, whole-mounted and photographed
under epifluorescent illumination. For size analysis, the area of the GFP+
outgrowths (defined by a continuous line around the outermost limit of the
outgrowth) was determined using ImageJ with reference to a scale bar. For
branching analysis, the number of branch points was counted in three
0.1 cm2 fields per view per gland. The small size and difficulty in obtaining
clear images of some outgrowths meant that not all of the outgrowths
analysed for size were available for branching analysis.
Mice were injected with control and knockdown cells in contralateral fat
pads (shLuc versus shPtprb pool; shScr1 versus shPtprb 0145; shScr1
versus shPtprb 3820) to control for variability in growth between animals
and variability in time at which glands were harvested, both of which will
affect the size of the final outgrowth.
For flow-sorting analysis, GFP+ outgrowths were dissected out and
processed to single cells, stained and analysed as described above. For
secondary transplantation, GFP+ outgrowths were dissected out, processed
to single cells and immediately re-transplanted. For histological analysis of
transplants, small (5 mm3) pieces of GFP+ outgrowths were dissected out,
formalin-fixed and paraffin embedded by standard methods. Dewaxed and
re-hydrated sections underwent antigen retrieval in citrate buffer (0.01 M,
pH 6.0) for 18 min in a microwave (900 W) before blocking in DAKO
REAL Peroxidase blocking solution for 10 min (Dako) for 30 min. Sections
were incubated in Mouse on Mouse (M.O.M) Mouse Ig blocking reagent
(Vector Laboratories, BMK-2202) for 60 min followed by primary antibody
for 60 min at room temperature, followed by M.O.M Biotinylated Anti-
mouse IgG Reagent for 10 min. The secondary antibody was detected by
application of Vectastain Elite ABC reagent for 5 min followed by
application of the chromogen 3,3’-diaminobenzidine (DAB) for 5 min
(ABC, Vector Laboratories). Primary antibodies used were anti-K8/18
(clone Ks18.04, mouse monoclonal; Progen Biotechnik, 61028; 1:2), anti-
SMA (clone 1A4, mouse monoclonal; Sigma, A5691; 1:500).
For immunofluorescence, sections were incubated in Mouse on Mouse
(M.O.M) Mouse Ig blocking reagent for 60 min, followed by overnight
incubation in primary antibody at 4°C. Primary antibody was detected with
an appropriate Alexa Fluor-conjugated secondary antibody. Images of
stained sections were captured using a Leica TCS-SP2 microscope in three
or four channels using Leica LCS software (Leica Microsystems). Negative
controls were performed using the same protocols with substitution of the
primary antibody with IgG matched controls. In double-staining
experiments, control single-stained sections in which either the primary
antibody was left out or the primary antibody was combined with the wrong
secondary antibody showed no staining. Primary antibodies used were anti-
SMA (clone 1A4, mouse monoclonal; Sigma, A5691; 1:500), anti-Ki67
(rabbit polyclonal; Abcam, ab16667; 1:300), anti-cleaved caspase-3 (rabbit
polyclonal; Cell Signaling Technology, 9661S; 1:100). Lung tissue from
mice treated with four doses of doxorubicin at 2.5 mg kg−1 and
cyclophosphamide at 40 mg kg−1 at 5-day intervals and then harvested
5 days after the final dose was used a positive control for cleaved caspase-3.
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Isolation and culture of mammary gland organoids
Cultures were prepared as previously described (Ewald et al., 2008; Fata
et al., 2007). Briefly, third and fourth mammary fat pad pairs were harvested
from virgin female 8- to 10-week-old FVBnmice. Fat pads were minced and
tissue shaken for 30-45 min at 37°C in 50 ml 1:1 DMEM:Ham’s F12
(Invitrogen), 5% FCS (PAA Laboratories) media with 3 mg/ml collagenase
A (Roche Life Sciences) and 3 mg/ml trypsin (Sigma). The collagenase
solution was centrifuged at 1500 rpm (xxx g) for 10 min, dispersed through
10 ml 1:1 DMEM:Ham’s F12, centrifuged at 1500 rpm for 10 min, and then
re-suspended in 5 ml 1 μg/ml DNase I (Sigma) in serum-free 1:1 DMEM:
Ham’s F12 medium. The DNase solution was shaken by hand at room
temperature for 2-5 min then centrifuged at 1500 rpm for 10 min. Organoids
were separated from single cells through four differential centrifugations
(pulse to 1500 rpm in 10 ml 1:1 DMEM:Ham’s F12). The final pellet was
re-suspended in the desired amount of Growth Factor ReducedMatrigel (BD
Biosciences) or 1:1 mix of Growth Factor Reduced Matrigel and lentivirus
or 1:1 DMEM:Ham’s F12 for non-infected controls.
Organoid assays were carried out in 24-well plates. Fifty microlitres of cold
Growth Factor Reduced Matrigel was laid onto a sterile 13 mm diameter
borosilicate glass coverslip and incubated for 30 min at 37°C to solidify. Fifty
microlitres of the organoid and Matrigel mix or organoid, Matrigel and
lentivirus mix was plated over the solidified Matrigel and the plate incubated
at 37°C for another 30 min. Once the Matrigel or 1:1 Matrigel:lentivirus mix
containing the organoids had set, the organoids were covered with minimal
media (1:1 DMEM:Ham’s F12, 5 µg/ml insulin (Sigma) or branching
medium (minimal medium+50 ng ml−1 FGF2 (Peprotech).AQ8
¶
ANG1 and
ANG2 were a kind gift of Dr Andy Reynolds (Institute of Cancer
Research, London, UK) and were also added at 50 ng ml−1. For lentiviral
transduction experiments, organoids with a minimum of ≥30% GFP-positive
cells were analysed, in line with previous studies (Macias et al., 2011).
Protein analysis
Transduced mammary organoids were serum starved for 12 h and left
unstimulated or stimulated with 10 ng/ml FGF2 for the indicated times.
ERK1/2 inhibitor SCH772984 was obtained from Selleckchem
(Newmarket, Suffolk, UK; S7101). Organoids were released from
Matrigel using non-enzymatic cell recovery solution (BD Biosciences)
and then lysed in Laemmli buffer (2% SDS, 10% glycerol, 1.25% β-
mercaptoethanol, 0.002% Bromophenol Blue, 0.0625 M Tris pH 6.8).
Following SDS-PAGE, protein extracts were transferred to a PVDF
membrane and probed with antibodies to p44/42 MAPK (ERK1/2) (Cell
Signaling Technology, 9102), phospho-p44/42 MAPK (ERK1/2) (Thr202/
Tyr204) (Cell Signaling Technology, 9101), phospho-FGF receptor
(Tyr653/654) (Cell Signaling Technology, 3471), FGFR1 (rabbit
monoclonal, clone D8E4; Cell Signaling Technology, 9740), FGFR2
(mouse monoclonal, clone 1G3; Abnova, H00002263-M01), FGFR3
(rabbit polyclonal; Thermo Fisher Scientific, PA5-34574), FGFR4 (rabbit
polyclonal; Sigma-Aldrich, HPA028251) or anti-tubulin (clone BM1A;
Sigma, T6199). After incubation with peroxidase-conjugated secondary
antibodies, immunocomplexes were detected using Enhanced
Chemiluminescent (ECL) reagents (xxx supplier? xxx). Densitometric
analysis was performed using ImageJ software.
Statistics
Significance of gene expression differences analysed by qRT-PCR were
determined using 95% confidence intervals as described (Cumming et al.,
2007). To test whether Ptprb knockdown decreased size of outgrowths but
increased branching, one-tailed unpaired t-tests were used. To determine
whether Ptprb knockdown increased levels of ERK1/2 and FGFR
phosphorylation in response to FGF2 stimulation, one-tailed unpaired
t-tests were used. To determine differences in organoid branching, χ2 test of
distribution of categorical variables was used.
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